High-dose immunoglobulin pulse therapy and risk of Covid19 infection
01 Pubblicazione su rivista
Prada V., Benedetti L., Cocito D., Briani C., Nobile Orazio E., Gallia F., Antonini G., Manganelli F., Fabrizi G. M., Germano F., Grandis M., Schenone A.
ISSN: 0340-5354
Therapy with hyperimmune plasma from recovered COVID19 patients has been suggested as a possible therapeutic approach. Intravenous immunoglobulins (IVIg) may harbour some protective effect. Patients undergoing IVIg or SCIg chronic treatments may have a reduced risk of contracting COVID-19 infection compared to patients receiving other immune therapies or no therapy.